Research programme: Alzheimer's disease therapies - BioFocus/Senexis

Drug Profile

Research programme: Alzheimer's disease therapies - BioFocus/Senexis

Alternative Names: β-sheet breakers

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Galapagos NV; Senexis
  • Class Small molecules
  • Mechanism of Action Amyloid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in United Kingdom (PO)
  • 12 Dec 2005 Senexis and Galapagos have expanded their collaboration to include optimisation of novel inhibitors of amyloid-induced toxicity and neuroinflammation in the UK for Alzheimer's disease
  • 04 Nov 2005 BioFocus has been acquired and merged into Galapagos NV
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top